hematopoiet
cell
transplant
hct
remain
potenti
cur
treatment
lifethreaten
hematolog
nonhematolog
diseas
last
sever
year
total
number
hct
perform
worldwid
exceed
year
niederwies
et
al
gratwohl
et
al
autolog
hematopoiet
cell
transplant
autohct
account
major
procedur
perform
unit
state
number
continu
increas
fast
rate
mainli
transplant
perform
plasma
cell
lymphoprolif
disord
extend
older
patient
gratwohl
et
al
center
intern
blood
marrow
transplant
research
cibmtr
allogen
hct
allohct
exceed
per
year
worldwid
number
transplant
recipi
surpass
year
unit
state
center
intern
blood
marrow
transplant
research
cibmtr
approxim
allogen
transplant
use
hematopoiet
progenitor
cell
hpc
volunt
unrel
donor
urd
advanc
hla
type
new
immunosuppress
protocol
improv
support
care
administr
nonmyeloabl
nma
reducedintens
condit
ric
regimen
contribut
increas
frequenc
hct
observ
continu
annual
increas
around
mainli
rise
allohct
urd
gratwohl
et
al
gratwohl
et
al
also
increas
altern
donor
sourc
hlahaploident
donor
exceed
umbil
cord
blood
transplant
center
intern
blood
marrow
transplant
research
cibmtr
although
cell
donat
apheresi
consid
rel
safe
procedur
low
rate
seriou
advers
event
schmidt
et
al
risk
physic
psycholog
harm
exist
time
also
potenti
harm
recipi
infus
graft
especi
communic
diseas
allogen
donor
import
optim
whole
donat
experi
donor
undergo
procedur
receiv
direct
benefit
howev
potenti
sens
satisfact
deriv
altruist
act
boo
et
al
therefor
urd
excel
reput
safe
effici
process
need
ensur
adequ
number
donor
maintain
join
nation
registri
billen
et
al
pretranspl
donor
evalu
essenti
process
safeguard
qualiti
safeti
donat
primari
goal
allohct
donor
evalu
ensur
minim
risk
health
donor
collect
procedur
b
protect
recipi
transmiss
diseas
may
us
food
drug
administr
fda
implement
comprehens
regul
govern
collect
manufactur
human
product
transplant
immun
modul
well
varieti
cellularand
tissuebas
human
product
food
drug
administr
regul
base
fda
respons
limit
transmiss
infecti
diseas
administr
product
appli
peripher
blood
stem
cell
cord
blood
donor
lymphocyt
respons
bone
marrow
regul
assign
health
resourc
servic
administr
hrsa
fda
regul
includ
requir
establish
donor
elig
appli
product
collect
manufactur
within
countri
also
import
outsid
unit
state
food
drug
administr
intern
regulatori
bodi
exampl
european
direct
donat
tissu
cellular
therapi
product
human
tissu
author
hta
regul
also
detail
requir
donor
evalu
ensur
safeti
product
recipi
howev
unlik
fda
regul
address
donor
safeti
issu
given
extens
intern
collabor
exchang
hpc
product
regulatori
agenc
work
close
nation
registri
nation
marrow
donor
program
nmdp
world
marrow
donor
associ
wmda
nation
registri
develop
establish
appropri
guidanc
ensur
hpc
donat
perform
safe
ethic
volunt
urd
publish
recommend
donor
evalu
sacchi
et
al
lown
et
al
nation
marrow
donor
program
nmdp
nda
donor
assess
suitabl
elig
donat
hpc
donor
suitabl
refer
gener
health
medic
fit
autolog
allogen
hpc
donor
undergo
collect
procedur
donor
evalu
risk
overal
safeti
donat
donor
elig
refer
issu
relat
allogen
donor
screen
test
complet
accord
applic
law
regul
determin
free
risk
factor
relev
communic
diseas
urd
elig
unrestrictedli
healthi
often
howev
physician
struggl
decis
make
suitabl
rel
donor
would
otherwis
meet
suitabl
criteria
unrel
donat
suitabl
criteria
relat
donor
rd
often
less
strict
consider
variabl
transplant
center
differ
rd
urd
may
exist
mobil
collect
practic
sacchi
et
al
confer
et
al
odonnel
et
al
clare
et
al
publish
data
suggest
risk
seriou
advers
event
reaction
might
higher
rd
urd
amount
adequ
prospect
data
rd
set
still
limit
halter
et
al
kodera
et
al
mani
institut
develop
process
evalu
rd
histor
nation
guidanc
avail
worldwid
network
blood
marrow
stand
committe
donor
issu
develop
consensu
document
recommend
donor
workup
final
clearanc
famili
donor
would
otherwis
abl
serv
urd
age
preexist
diseas
worel
et
al
factjaci
foundat
accredit
cellular
therapyjoint
accredit
committe
isct
ebmt
intern
standard
found
address
obstacl
face
transplant
involv
donor
recipi
differ
countri
voluntari
organ
establish
intern
guidelin
collect
transfer
hematopoiet
stem
cell
member
includ
donor
registri
cord
blood
registri
numer
individu
work
togeth
advanc
hct
factjaci
address
issu
includ
donor
evalu
criteria
donor
followup
polici
requir
allogen
donor
suitabl
evalu
physician
physician
recipi
accredit
mean
center
demonstr
perform
requir
level
practic
accord
agre
standard
excel
essenti
allow
center
certifi
oper
effect
qualiti
manag
system
mani
countri
howev
accredit
mandatori
center
assess
rd
improv
complianc
intern
recogn
donor
care
paradigm
seen
center
factjaci
accredit
howev
import
practic
gap
center
irrespect
accredit
continu
seen
anthia
et
al
b
organ
provid
addit
insight
us
regul
regard
donor
evalu
includ
aabb
american
societi
blood
marrow
transplant
asbmt
intern
societi
cellular
therapi
isct
center
intern
blood
marrow
transplant
research
cibmtr
similar
blood
transfus
hpc
donat
potenti
transmit
wide
rang
bloodborn
diseas
exampl
hepat
b
lau
et
al
hepat
c
strasser
mcdonald
shuhart
et
al
human
tlymphotroph
viru
type
type
kikuchi
et
al
ljungman
et
al
chaga
diseas
villalba
et
al
malaria
mejia
et
al
syphili
naohara
et
al
brucellosi
ertem
et
al
report
transmit
hpc
unit
state
strict
feder
regul
regard
evalu
hpc
donor
laid
titl
code
feder
regul
part
human
cell
tissu
cellularand
tissuebas
product
subpart
c
donor
elig
determin
lay
requir
donor
screen
test
relev
communic
diseas
agent
diseas
rcdad
tabl
relev
communic
diseas
agent
diseas
rcdad
identifi
fda
potenti
caus
signific
pathogen
recipi
human
cell
tissu
cellularand
tissuebas
product
defin
infect
fda
identifi
specif
rcdad
list
either
specif
cfr
publish
guidanc
document
commun
chang
institut
accredit
bodi
may
choos
includ
evalu
agent
diseas
malaria
determin
elig
donor
need
screen
test
rcdad
assess
risk
diseas
transmiss
involv
three
compon
food
drug
administr
target
screen
histori
examin
physic
sign
diseas
laboratori
test
specif
pathogen
trait
screen
histori
involv
interview
donor
medic
histori
relev
social
behavior
includ
review
relev
medic
record
clinic
evid
rcdad
fda
recommend
screen
interview
document
dialogu
administ
phone
person
appropri
followup
verif
train
individu
donor
health
histori
selfadminist
variou
registri
develop
hpc
donorscreen
questionnair
use
recommend
elicit
medic
histori
identifi
highrisk
behavior
associ
risk
diseas
transmiss
aabb
nda
nation
marrow
donor
program
screen
histori
also
includ
communic
diseas
risk
associ
xenotransplant
one
questionnair
freeli
avail
hematopoiet
progenitor
cell
hpc
apheresi
hpc
marrow
donor
histori
questionnair
dhq
appendix
develop
aabb
interorganiz
dhqhpc
task
forc
provid
establish
standard
tool
screen
allogen
hpc
donor
communic
diseas
risk
factor
accord
requir
fda
aabb
fact
nmdp
aabb
nda
dhq
materi
period
review
ensur
continu
complianc
regulatori
accredit
agenc
companion
document
provid
rational
question
recommend
evalu
respons
aabb
ndb
institut
notifi
chang
well
timelin
implement
exist
public
websit
maintain
member
task
forc
new
version
document
post
previou
version
maintain
period
time
allow
facil
transit
new
version
nmdp
develop
similar
medic
histori
questionnair
support
work
unrel
donor
http
networkbethematchclinicalorgworkareadownloadasset
nd
process
complet
dhq
clinic
staff
must
verbal
interact
donor
review
verifi
donor
respons
dhq
ensur
dhq
sign
date
donor
appropri
agerel
donor
health
questionnair
parent
legal
guardian
proxi
requir
age
appropri
arrang
must
made
donor
development
delay
appropri
interpret
nonnationalspeak
patient
donor
english
nativ
speak
countri
assess
medic
interpret
famili
member
friend
famili
physic
examin
perform
identifi
sign
stigmata
may
indic
highrisk
behavior
infect
rcdad
examin
includ
recent
tattoo
pierc
sign
intraven
drug
use
well
sign
signific
ill
determin
elig
donat
procedur
sever
institut
develop
supplement
examin
checklist
appendix
ensur
thorough
examin
sign
stigmata
rcdad
accord
fda
regul
laboratori
test
use
fdaapprov
assay
must
perform
donor
blood
least
follow
infecti
diseas
agent
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
hcv
treponema
pallidum
syphili
human
tcell
lymphotroph
viru
ii
htlv
ii
cytomegaloviru
cmv
fda
provid
core
requir
laboratori
test
tabl
emerg
infecti
diseas
includ
zika
viru
zikv
sever
acut
respiratori
syndrom
sar
west
nile
viru
wnv
addit
screen
question
emerg
ad
donor
qualif
process
unit
state
base
upon
recommend
fda
wnv
infecti
virem
phase
nat
test
must
perform
concomitantli
product
collect
within
day
collect
might
possibl
prevent
infus
infect
product
know
product
infect
wnv
would
provid
opportun
develop
preemptiv
treatment
strategi
unit
state
wnv
test
perform
specif
june
octob
year
establish
intend
import
human
cell
tissu
cellularand
tissuebas
product
unit
state
test
human
cell
tissu
cellularand
tissuebas
product
donor
wnv
perform
yearround
also
desir
perform
test
prior
infect
varicella
zoster
viru
vzv
epsteinbarr
viru
ebv
possibl
other
tabl
laboratori
use
laboratori
test
must
certifi
clinic
laboratori
improv
amend
usc
cfr
part
equival
requir
determin
center
medicar
medicaid
servic
cm
test
must
perform
accord
manufactur
instruct
use
ifu
hematopoiet
stemprogenitor
cell
hspc
donor
laboratori
specimen
use
donor
test
may
collect
day
prior
within
day
human
cell
tissu
cellularand
tissuebas
product
recoveri
cell
tissu
donor
laboratori
test
must
perform
day
recoveri
toxoplasmosi
posit
test
exposur
agent
may
preclud
donat
make
donor
inelig
may
modifi
transplant
approach
posttranspl
surveil
strategi
rcdad
screen
result
commun
effect
collect
center
well
physician
respons
accept
human
cell
tissu
cellularand
tissuebas
product
notif
part
standard
procedur
clearli
document
human
cell
tissu
cellularand
tissuebas
product
donor
whose
specimen
test
posit
reactiv
use
assay
consid
inelig
except
syphili
cmv
screen
confirmatori
test
consid
posit
reactiv
screen
test
result
receiv
purpos
donor
counsel
investig
discord
test
result
confirmatori
test
perform
neg
nonreact
result
would
overrid
posit
reactiv
screen
test
donor
still
remain
inelig
screen
test
syphili
except
potenti
falseposit
result
nontreponem
test
specif
treponem
confirmatori
test
neg
donor
deem
elig
syphili
standpoint
donor
test
posit
reactiv
cmv
necessarili
inelig
donat
human
cell
tissu
cellularand
tissuebas
product
posit
reactiv
past
recent
exposur
igg
igm
cmv
test
result
also
commun
physician
respons
accept
human
cell
tissu
cellularand
tissuebas
product
case
posit
igm
cmv
best
exclud
cmv
seroconvers
complet
donor
elig
screen
histori
physic
examin
laboratori
test
written
donor
elig
determin
requir
human
cell
tissu
cellularand
tissuebas
product
donor
except
autolog
use
human
cell
tissu
cellularand
tissuebas
product
must
transplant
infus
transfer
donor
determin
elig
unless
appropri
donor
propos
donor
pose
less
risk
recipi
use
donor
approv
obtain
recipi
proceed
transplant
use
cell
often
pose
concern
inform
donor
health
strictli
confidenti
releas
explicit
permiss
donor
hpc
collect
proce
inelig
donor
written
justif
need
shall
document
result
rcdad
screen
test
must
review
prior
initi
prepar
condit
therapi
recipi
time
initi
donor
evalu
collect
delay
repeat
test
may
necessari
event
miss
incomplet
screen
test
result
time
hpc
collect
product
label
clearli
collect
center
product
evalu
infecti
diseas
marker
donor
declar
inelig
process
center
polici
procedur
place
storag
releas
inelig
donor
product
donor
must
medic
evalu
detect
condit
might
significantli
increas
donor
risk
unaccept
level
ensur
safeti
donat
peripher
blood
hematopoiet
progenitor
cell
hpc
donat
typic
involv
administr
daili
inject
granulocytecoloni
stimul
factor
gcsf
andor
mobil
agent
follow
apheresi
collect
autolog
patient
mobil
commonli
includ
gcsf
plerixafor
chemotherapi
side
effect
hpc
mobil
gcsf
mobil
agent
apheresi
collect
taken
consider
assess
donor
suitabl
design
physician
appropri
licens
supervis
advanc
practition
perform
medic
histori
physic
examin
accord
standard
medic
practic
medic
record
also
review
part
assess
histori
provid
addit
opportun
review
affirm
question
provid
donor
screen
health
questionnair
look
evalu
current
health
typic
question
cover
histori
take
seen
tabl
physic
examin
also
includ
assess
signsstigmata
rcdad
appendix
vital
sign
test
height
weight
note
karnofskyor
lanskyperform
score
assess
venou
access
essenti
part
physic
examin
laboratori
test
investig
also
requir
evalu
donor
suitabl
tabl
nmdp
develop
sever
tool
list
clinic
disordersdiseas
assess
urd
donor
health
rcdad
risk
nation
marrow
donor
program
nmdp
nda
sever
center
often
use
tool
guidanc
rd
donor
atyp
respons
screen
question
histori
physic
examin
must
evalu
casebycas
basi
determin
donor
elig
suitabl
individu
perform
evalu
health
screen
histori
pe
knowledg
train
experi
accept
defer
donor
gener
donor
moder
sever
organ
impair
defer
includ
donor
coronari
arteri
diseas
renal
hepat
impair
occasion
medic
condit
identifi
warrant
complet
blood
count
cbc
differenti
reticulocyt
count
electrolyt
na
k
co
chlorid
blood
urea
nitrogen
bun
creatinin
alkalin
phosphatas
lactat
dehydrogenas
ldh
alanin
aminotransferas
alt
sgpt
glucos
serum
total
protein
plu
albumin
serum
protein
electrophoresi
abo
rh
type
antibodi
screen
infecti
diseas
marker
idm
see
cmv
antibodi
screen
see
text
serum
betahcg
pregnanc
femal
childbear
potenti
malari
test
donor
travel
malaria
endem
area
screen
hemoglobinopathi
eg
sickledex
equival
donat
thalassemia
patient
thalassemia
screen
hemoglobin
f
urinalysi
tuberculosi
test
clinic
indic
oxygen
satur
chest
xray
ekg
clinic
indic
chest
xray
ekg
routin
requir
howev
may
perform
discret
examin
medic
profession
collect
facilitydonor
center
physician
base
medic
assess
criteria
perform
ekg
may
includ
histori
diabet
mellitu
dm
histori
cardiovascular
diseas
cvd
treatment
digoxin
diuret
pulmonari
diseas
room
air
smoke
pack
year
age
male
femal
delay
donor
collect
day
repeat
ekg
may
requir
certain
case
histori
dm
cvd
treatment
digoxin
diuret
otherwis
donor
repeat
month
sinc
last
ekg
criteria
perform
chest
xray
may
includ
histori
pulmonari
diseas
oxygen
satur
immedi
deferr
may
requir
investig
referr
specialist
addit
workup
requir
expedit
recipi
team
inform
soon
possibl
transplant
clinician
determin
whether
donor
found
suitabl
would
avail
time
manner
donor
deem
unsuit
decis
made
suitabl
donor
avail
donor
prepar
take
reason
risk
justif
must
document
event
transplant
procedur
delay
collect
transplant
facil
may
requir
repeat
donor
assess
within
specifi
time
nmdp
requir
donor
assess
alway
current
within
week
month
propos
collect
date
includ
repeat
administr
screen
questionnair
addit
test
ensur
continu
medic
suitabl
base
updat
inform
provid
mandatori
test
nmdp
requir
extend
test
less
month
pass
sinc
origin
physic
examin
date
laboratori
marker
rcdad
howev
need
repeat
within
day
collect
hpc
tabl
addit
risk
recipi
safeti
follow
donat
infecti
diseas
need
assess
evalu
donor
includ
autoimmun
diseas
ad
inherit
diseas
malign
develop
ai
disord
donor
condit
report
includ
thyroid
diseas
olivar
et
al
thomson
et
al
diabet
mellitu
lampet
et
al
psoriasi
snowden
heaton
vitiligo
campbellfontain
et
al
inherit
diseas
within
hematopoiet
system
transmit
includ
hemoglobinopathi
sickl
cell
diseas
thalassemia
congenit
platelet
disord
inherit
bone
marrow
failur
syndrom
transmiss
malign
diseas
donor
patient
report
past
inadvert
subclin
malign
diseas
diseas
recogn
current
screen
method
risk
transmiss
tumor
assum
low
incid
rate
includ
secondari
malign
donor
cell
origin
aris
recipi
allohct
addit
patient
histori
heparin
allergi
heparin
intoler
heparininduc
thrombocytopenia
increas
risk
complic
infus
heparincontain
product
essenti
import
heparin
use
part
anticoagul
apheresi
collect
process
donor
evalu
provid
ideal
opportun
get
full
inform
consent
donor
would
requir
comprehens
discuss
potenti
risk
theoret
donor
safeti
issu
donor
awar
oblig
donat
even
famili
member
coercion
essenti
allogen
donor
suitabl
evalu
physician
physician
recipi
donor
consent
donat
choos
pull
decis
recipi
start
condit
treatment
potenti
risk
recipi
discuss
fulli
donor
suitabl
donor
younger
patient
undergo
allohct
often
minor
sibl
rare
case
children
may
also
consid
potenti
donor
adult
sibl
parent
famili
member
worldwid
data
indic
children
undergo
hct
receiv
allograft
sibl
age
miano
et
al
use
minor
hpc
donor
consid
medic
safe
pulsiph
et
al
legal
accept
given
altern
approach
compar
effect
exist
howev
donat
hpc
without
risk
pulsiph
et
al
styczynski
et
al
grupp
et
al
appropri
medic
evalu
donor
essenti
sourc
graft
peripher
blood
vs
bone
marrow
greatest
influenc
type
advers
event
may
present
import
note
children
major
graft
bone
marrow
origin
side
effect
includ
pain
either
gcsf
treatment
placement
central
venou
cathet
cvc
punctur
wound
made
harvest
bone
marrow
young
donor
requir
cvc
apheresi
thu
expos
potenti
risk
bleed
infect
pneumothorax
complic
sedat
gener
anesthesia
pulsiph
et
al
styczynski
et
al
collect
peripher
blood
graft
requir
special
attent
children
use
growth
factor
main
issu
longterm
advers
effect
brief
treatment
cours
gcsf
harvest
hpc
via
apheresi
continu
studi
ongo
investig
date
convinc
evid
shown
signific
health
risk
pulsiph
et
al
worldwid
network
blood
marrow
transplant
wbmt
recommend
gcsf
use
caution
need
emphas
need
longterm
followup
donor
halter
et
al
sever
publish
find
suggest
pediatr
donor
may
experi
psychosoci
issu
around
time
follow
donat
includ
higher
anxieti
lower
selfesteem
nondonor
packman
et
al
moder
level
posttraumat
stress
depress
behavior
problem
ident
problem
guilt
resent
packman
et
al
packman
et
al
wiener
et
al
young
donor
may
also
fear
medic
aspect
pain
involv
donat
experi
anxieti
ambival
donat
kinrad
macleod
et
al
although
parent
major
consent
medic
intervent
behalf
children
respect
child
autonomi
obtain
child
assent
appropri
regard
dissent
refusali
gener
thought
paramount
ethic
import
decis
maker
burden
great
respons
choic
lifeanddeath
consequ
anoth
vulner
child
recogn
hpc
donat
physic
benefit
young
donor
associ
potenti
risk
american
academi
pediatr
committe
bioethic
aapcob
committe
bioethic
publish
guidelin
specifi
minor
may
ethic
serv
hpc
donor
aapcob
deem
children
may
ethic
serv
hematopoiet
stem
cell
donor
five
criteria
fulfil
tabl
donor
advoc
expertis
pediatr
develop
second
physician
child
life
specialist
appoint
children
reach
age
major
age
person
recogn
state
law
adult
evalu
hematopoiet
graft
donor
donor
advoc
must
independ
team
respons
direct
care
recipi
ensur
aapcob
recommend
met
ideal
involv
onset
start
decis
whether
minor
undergo
hla
test
potenti
famili
sibl
donor
medic
psycholog
reason
donat
would
hla
type
donor
medic
condit
care
examin
skill
profession
risk
complic
collect
increas
defer
advanc
effect
differ
hematopoiet
stem
cell
transplant
research
often
need
perform
donor
andor
recipi
donor
minor
research
must
conform
feder
regul
govern
pediatr
subject
may
requir
nation
review
research
impos
minim
risk
without
prospect
direct
benefit
donor
subject
sever
public
address
area
consid
donor
evalu
research
wendler
et
al
shah
et
al
increas
avail
nma
condit
last
two
decad
pingali
champlin
alyea
et
al
improv
support
care
abil
mani
older
patient
toler
allohct
becom
appar
older
patient
hlamatch
sibl
often
donor
unlik
urd
registri
strict
age
limit
recommend
relat
allogen
donor
experi
avail
literatur
donor
age
year
mani
health
disord
preval
increas
chronolog
age
includ
cardiovascular
cerebrovascular
peripher
vascular
diseas
chronic
airway
diseas
diabet
mellitu
malign
etc
must
taken
consider
provid
assess
suitabl
older
individu
donat
report
hpc
collect
apheresi
seem
safe
procedur
donor
includ
signific
comorbid
ghada
et
al
howev
certain
complic
frequent
older
donor
demonstr
procedur
relat
complic
younger
donor
et
al
exampl
one
studi
demonstr
higher
complic
associ
medic
equival
histocompat
adult
rel
will
abl
donat
strong
person
emot
posit
relationship
donor
recipi
reason
likelihood
recipi
benefit
clinic
emot
psychosoci
risk
donor
minim
reason
relat
benefit
expect
accru
donor
recipi
parent
permiss
appropri
child
assent
obtain
hypocalcemia
thrombocytopenia
problem
venou
access
donor
year
age
compar
younger
donor
vs
p
venou
access
complic
also
frequent
present
donor
circulatori
system
diseas
arteri
hypertens
chronic
venou
insuffici
compar
donor
without
medic
histori
vs
p
et
al
recent
relateddonor
safeti
studi
look
healthrel
qualiti
life
issu
among
older
relat
hct
donor
year
compar
younger
adult
counterpart
show
differ
indic
physic
mental
health
donationrel
experi
switzer
et
al
may
suggest
older
sibl
donor
experi
donat
process
significantli
physic
psycholog
impact
younger
counterpart
aspect
experi
positivefor
exampl
less
donationrel
pain
less
anxieti
donat
less
conclus
evid
support
procedur
sibl
donor
old
switzer
et
al
regard
graft
composit
author
found
older
donor
may
differ
obtain
younger
donor
alali
et
al
richa
et
al
miller
cell
peripher
blood
apheresi
yield
lower
older
donor
richa
et
al
suzuya
et
al
one
studi
note
failur
mobil
collect
less
cellskg
recipi
bodi
weight
rate
older
donor
group
year
versu
younger
donor
group
note
howev
donor
younger
year
relationship
statist
signific
longer
independ
prognost
factor
also
seen
studi
ing
et
al
sever
studi
howev
report
contradictori
result
regard
donorpredict
factor
mobil
yield
confirm
independ
influenc
age
mobil
bagnara
et
al
miflin
et
al
rinaldi
et
al
suggest
conflict
result
like
due
often
small
sampl
size
heterogen
treatment
mobil
regimen
et
al
autolog
transplant
elderli
patient
high
risk
poor
mobil
goker
et
al
studi
report
cell
mobil
patient
advanc
age
year
older
multipl
myeloma
poor
still
possibl
morri
et
al
contrari
report
suggest
differ
mobil
kinet
younger
year
older
year
myeloma
patient
jantunen
et
al
investig
whether
age
affect
mobil
autolog
transplant
also
contradictori
donor
year
old
bensing
et
al
bensing
et
al
therefor
age
confound
factor
autolog
stem
cell
mobil
sever
donor
factor
predict
outcom
allohct
age
one
import
nonhla
factor
affect
surviv
rate
transplant
kollman
et
al
clinic
practic
often
prefer
hlamatch
sibl
firstlin
donor
transplant
despit
donor
age
howev
surviv
rate
unrel
donor
transplant
young
fulli
hla
compat
donor
similar
use
older
sibl
donor
kollman
et
al
allohct
older
adult
associ
higher
nonrelaps
mortal
nrm
donor
age
associ
relaps
kollman
et
al
observ
higher
rate
grade
ii
iv
acut
gvhd
transplant
graft
older
donor
may
explain
replac
tcell
memori
tcell
immun
system
age
older
donor
miller
occas
match
relat
donor
identifi
may
individu
known
psychologicalpsychiatr
disord
decis
physician
deem
prospect
donor
suitabl
may
difficult
inde
wbmt
stand
committe
donor
issu
held
intern
workshop
develop
consensu
document
recommend
suitabl
criteria
final
donor
workup
famili
donor
includ
donor
psychologicalpsychiatr
disord
worel
et
al
recommend
well
recruit
assess
tool
use
nmdp
registri
may
help
physician
concern
suitabl
donor
nation
marrow
donor
program
nmdp
nd
ndb
donor
histori
substanc
abus
may
automat
defer
requir
care
histori
medic
assess
donor
assess
risk
factor
infecti
diseas
underli
psychiatr
disord
compuls
depend
chemic
caus
variou
physic
ailment
liver
damag
secondari
alcohol
abus
case
infrequ
substanc
abus
marijuana
alon
individu
mostli
suitabl
may
requir
cessat
use
donat
initi
gcsf
donor
previou
histori
current
use
cocain
crack
methamphetamin
intranasalor
abus
might
also
suitabl
howev
use
drug
associ
increas
risk
cardiovascular
disord
care
assess
donor
requir
intraven
drug
abus
donat
gener
recommend
due
increas
risk
communic
diseas
hiv
hepat
b
hepat
c
contamin
needl
individu
substitut
program
otherwis
healthi
may
suitabl
donor
eat
disord
anorexia
andor
bulimia
suitabl
diseas
stabl
appropri
treatment
bmi
adult
worel
et
al
potenti
donor
defer
overal
physic
statu
includ
bodi
size
demeanor
skin
color
etc
indic
seriou
health
concern
hpc
donat
individu
multipl
person
disord
psychosi
gener
recommend
subject
obsessivecompuls
attent
deficit
attentiondeficit
hyperact
disord
suitabl
diseas
well
control
howev
donor
capac
follow
donat
process
may
affect
donor
underli
psychiatr
disord
anxieti
depress
bipolar
disord
donor
concern
donor
may
followthrough
donat
bone
marrow
harvest
procedur
may
question
apheresi
collect
cryopreserv
consid
advanc
condit
regimen
start
certain
medic
may
potenti
defer
donat
render
donor
inelig
tabl
due
concern
potenti
rcdad
transmit
transfus
hct
donor
would
declar
inelig
may
abl
donat
depend
institut
practic
major
potenti
donor
usual
medic
take
like
concern
rather
underli
medic
condit
treatment
prescrib
may
make
donor
unsuit
donat
certain
medic
would
potenti
increas
donor
recipi
risk
often
also
requir
treat
medic
condit
would
like
defer
donor
well
tabl
certain
medic
donor
medic
condit
well
control
donor
may
suitabl
proceed
donat
tabl
donor
lithium
due
interact
gcsf
hpc
collect
use
apheresi
gener
allow
donor
may
consid
evalu
marrow
donat
donor
recipi
past
allerg
reaction
heparin
histori
heparininduc
thrombocytopenia
hit
donor
may
donat
apheresi
howev
anticoagul
use
circuit
product
acda
ie
citrat
alon
human
growth
hormon
concern
creutzfeldtjakob
diseas
cjd
donor
diabet
previous
receiv
bovin
insulin
concern
new
variant
cjd
agent
respons
bovin
spongiform
encephalopathi
bse
mad
cow
diseas
hepat
b
immun
globulin
hbig
use
prevent
infect
follow
exposur
hbv
hbig
prevent
hbv
infect
everi
case
donor
taken
last
month
hbv
still
transmit
unlicens
vaccin
usual
associ
research
protocol
effect
regard
stem
cell
recipi
unknown
fda
identifi
zikv
rcdad
potenti
risk
transmiss
zikv
hctp
support
evid
zikv
detect
tissu
semen
placenta
march
fdaclear
diagnost
test
zikv
avail
fda
provid
donor
screen
recommend
reduc
risk
transmiss
zikv
hctp
food
drug
administr
donor
hctp
consid
inelig
medic
diagnosi
zikv
infect
past
month
resid
travel
area
activ
zikv
transmiss
within
past
month
donor
also
declar
inelig
sex
within
past
month
male
known
either
risk
factor
first
blood
transfus
transmiss
report
brazil
four
transmiss
occur
three
donor
august
fda
issu
revis
guidanc
recommend
blood
center
state
unit
state
territori
screen
individu
unit
donat
whole
blood
blood
compon
bloodscreen
test
author
use
fda
investig
new
drug
ind
applic
licens
test
avail
late
blood
center
began
implement
investig
blood
test
nucleic
acid
test
goodnough
marqu
april
remain
commerci
avail
diagnost
test
clear
fda
detect
zikv
current
test
ind
includ
serolog
test
assess
whether
individu
may
recent
expos
zikv
actual
infect
pcr
nat
test
diagnos
acuteact
zikv
infect
current
mandat
perform
laboratori
test
zikv
hct
ps
howev
sever
center
current
use
ind
serolog
nat
test
avail
event
laboratori
test
perform
attent
given
follow
donat
hpc
wellrecogn
regul
procedur
perform
thousand
patient
donor
throughout
world
annual
donat
autolog
hpc
part
treatment
plan
highdos
therapi
patient
aim
potenti
cure
least
prolong
remiss
underli
malign
aim
donat
hpc
rescu
patient
marrow
myeloabl
chemotherapi
receiv
time
transplant
patient
need
reason
medic
fit
receiv
patient
suitabl
hpc
collect
often
determin
time
deem
patient
suitabl
candid
autohct
major
sever
complic
often
associ
pancytopenia
accompani
chemomobil
result
well
predict
cytokin
mobil
collect
sever
center
collect
autolog
donor
hpc
use
gcsf
withwithout
plerixafor
mobil
agent
patient
need
assess
suitabl
donat
howev
hpc
infus
less
concern
transmiss
communic
diseas
elig
donat
need
food
drug
administr
allogen
hpc
donat
safe
procedur
low
rate
seriou
advers
event
side
effect
commonli
face
donat
transient
major
relat
unrel
donor
howev
sever
donationrel
death
halter
et
al
mostli
relat
donor
set
major
fatal
seriou
advers
event
occur
donor
preexist
medic
issu
suspect
robust
donor
assess
procedur
reduc
fatal
complic
therefor
donor
must
care
evalu
fulli
inform
prior
hpc
donat
clinician
good
understand
potenti
physic
psycholog
complic
factor
may
increas
risk
discuss
donor
must
also
abl
provid
inform
consent
without
coercion
pressur
medic
evalu
allogen
donor
never
conduct
physician
transplant
team
care
recipi
addit
suitabl
determin
donor
elig
determin
also
essenti
physician
evalu
allogen
donor
date
regul
law
govern
screen
requir
rcdad
import
particularli
emerg
new
diseas
seen
wnv
sar
zikv
sever
regulatori
agenc
registri
accredit
bodi
ensur
step
taken
improv
donor
patient
safeti
alik
nation
intern
registri
continu
provid
updat
recommend
safe
select
unrel
donor
provid
tool
recent
guidanc
could
extrapol
use
relat
donor
set
sacchi
et
al
lown
et
al
worel
et
al
donor
collect
center
encourag
enrol
accredit
bodi
factjaci
aabb
enabl
potenti
improv
standard
donor
evalu
collect
well
ensur
continu
improv
qualiti
manag
system
despit
surviv
rate
nearli
similar
match
urd
sibl
rd
hct
horowitz
higher
incid
gvhd
often
assum
match
sibl
transplant
physician
first
choic
major
transplant
indic
light
well
notabl
increas
use
relat
hlahaploident
transplant
center
intern
blood
marrow
transplant
research
cibmtr
rd
continu
need
appropri
evalu
medic
suitabl
donat
continu
concern
heterogen
care
relat
hpc
donor
odonnel
et
al
chang
fact
standard
foundat
accredit
cellular
therapi
fact
address
issu
sinc
improv
practic
adult
relateddonor
care
anthia
et
al
b
howev
still
appear
particular
concern
includ
counsel
assess
donor
hla
type
use
unlicens
mobil
agent
absenc
longterm
donor
followup
odonnel
et
al
world
marrow
donor
associ
wmda
bring
forward
compel
argument
manag
rd
perform
donor
registri
offer
establish
structur
donor
care
extens
experi
medic
evalu
donor
particular
suggest
signific
consider
registri
provis
central
donor
followup
anthia
et
al
donor
longterm
followup
import
aspect
donor
evalu
develop
follow
donor
integr
part
donor
program
allow
vigil
surveil
donat
improv
knowledg
risk
donat
end
us
appeal
court
rule
legal
pay
apheresi
donor
hpc
medpag
today
unlik
bone
marrow
tissu
felt
peripher
blood
hpc
differ
bodi
fluid
like
semen
plasma
nation
organ
transplant
act
nota
prohibit
paid
donor
concess
spirit
nota
deem
compens
could
form
cash
rather
voucher
appli
thing
scholarship
educ
hous
donat
chariti
wmda
put
posit
statement
hpc
donor
paid
boo
et
al
reason
includ
ethic
concern
rais
remuner
potenti
damag
public
act
altruist
potenti
coercion
exploit
donor
increas
risk
patient
harm
local
transplant
program
intern
stem
cell
exchang
povssibl
benefit
patient
disadvantag
other
transplant
medic
procedur
involv
expos
live
cell
tissu
organ
anim
sexual
partner
member
household
ever
transplant
medic
procedur
involv
expos
live
cell
tissu
organ
anim
rel
creutzfeldtjakob
diseas
area
evalu
document
histori
physic
examin
h
p
potenti
allogeneicsyngen
donor
peripher
blood
stem
cell
marrow
note
comment
locat
sever
andor
physic
find
physic
evid
nonmed
percutan
drug
use
needl
track
includ
examin
tattoo
may
cover
needl
track
comment
physic
evid
recent
tattoo
ear
pierc
bodi
pierc
comment
oral
thrush
comment
blue
purpl
spot
consist
kaposi
sarcoma
comment
unexplain
jaundic
hepatomegali
icteru
comment
physic
evid
sepsi
unexplain
gener
rash
comment
larg
scab
consist
recent
smallpox
immun
comment
gener
vesicular
rash
gener
vaccina
comment
sever
necrot
lesion
consist
vaccina
necrosum
comment
